ViCentra has successfully closed a EUR 65 million Series C funding round to facilitate the commercial launch of its innovative Kaleido insulin pump system across Europe.
Target Company Overview
ViCentra B.V., headquartered in Utrecht, Netherlands, is a pioneering company in the development of next-generation insulin pumps aimed at improving diabetes management. With its flagship product, the Kaleido insulin pump, ViCentra stands out in the market as the world’s smallest and lightest wearable insulin delivery system, designed to enhance the quality of life for individuals living with diabetes. Founded in 2013, the company is backed by several notable investors committed to supporting its mission of designing innovative healthcare solutions.
The Kaleido insulin pump has received CE marking and is commercially available in select European countries. ViCentra's commitment to continuous innovation is exemplified by the recent launch of its advanced Kaleido system, which integrates with Diabeloop’s DBLG1 solution for automated insulin delivery, representing a significant advancement in diabetes care technology.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Netherlands
The diabetes care market in the Netherlands is rapidly evolving, driven by increasing awareness of diabetes management and a growing population affected by the disease. According to the World Health Organization, approximately 422 million people worldwide have dia
Similar Deals
Proclin Nederland → Tandartsenpraktijk van P.P.I. Kennemerland
2025
Partners in Equity
invested in
ViCentra
in 2021
in a Other deal
Disclosed details
Transaction Size: $74M